ESSENTIAL PHARMACOGENOMIC PRODUCTS OR SERVICES Sample Clauses

ESSENTIAL PHARMACOGENOMIC PRODUCTS OR SERVICES. Subject to the terms and conditions of this Agreement and any applicable Burdened Technology Obligations, and on a product-by-product or service-by-service basis, Millennium hereby grants to Aventis a worldwide, non-exclusive, non-royalty-bearing license, under Millennium's rights to the Program Intellectual Property, to Commercialize Essential Pharmacogenomic Products or Services in the Territory. Such license shall further include the right to grant sublicenses to Affiliates of Aventis and to Third Parties in accordance with the terms set forth in Section 7.2.5.
Sample 1
AutoNDA by SimpleDocs
ESSENTIAL PHARMACOGENOMIC PRODUCTS OR SERVICES. Subject to the terms and conditions of this Agreement and any applicable Burdened Technology Obligations, and on a compound-by-compound basis, Millennium hereby grants to Aventis a worldwide, non-exclusive, non-royalty-bearing license, under Millennium's rights to the Program Intellectual Property, to use Scientifically-Qualified Targets to Develop Essential Pharmacogenomic Products or Services. Such license shall further include the right to grant sublicenses to Affiliates of Aventis and to Third Parties in accordance with the terms set forth in Section 7.2.5. Confidential Materials omitted and filed with the Securities and Exchange Commission. Asterisks denote omissions.
Sample 1

Related to ESSENTIAL PHARMACOGENOMIC PRODUCTS OR SERVICES

  • Product The term “

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Products 1.1. The information (including but not limited to the quantity, rated hashrate, unit price (“Unit Price”), total price for one item (“Total Price (One Item)”), total price for all the items (“Total Purchase Price”) of Products to be purchased by Party B from Party A is as follows (“Products”):

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Competing Products The provisions of Section 21 are set forth on attached Exhibit H and are incorporated in this Section 21 by this reference.

  • Manufacturing Services Jabil will manufacture the Product in accordance with the Specifications and any applicable Build Schedules. Jabil will reply to each proposed Build Schedule that is submitted in accordance with the terms of this Agreement by notifying Company of its acceptance or rejection within three (3) business days of receipt of any proposed Build Schedule. In the event of Jabil’s rejection of a proposed Build Schedule, Jabil’s notice of rejection will specify the basis for such rejection. When requested by Company, and subject to appropriate fee and cost adjustments, Jabil will provide Additional Services for existing or future Product manufactured by Jabil. Company shall be solely responsible for the sufficiency and adequacy of the Specifications [***].

  • Products and Services Part 2.9(a) of the Disclosure Schedule accurately identifies and describes each Company Product currently being designed, developed, manufactured, marketed, distributed, provided, licensed, or sold by the Company.

  • API A. Reliant shall supply to Cardinal Health for Manufacturing and Packaging, at Reliant’s sole cost, the API and applicable reference standards in quantities sufficient to meet Reliant’s requirements for each Product as further set forth in Article 4. Prior to delivery of any of the API or reference standard to Cardinal Health for Manufacturing and Packaging, Reliant shall provide to Cardinal Health a copy of the API Material Safety Data Sheet (“MSDS”), as amended, and any subsequent revisions thereto. Reliant shall supply the API, reference standards, and Certificate of Analysis FOB the Facility no later than thirty (30) days before the scheduled Manufacture Date upon which such API will be used by Cardinal Health. Upon receipt of the API, Cardinal Health shall conduct identification testing of the API. Cardinal Health shall use the API solely and exclusively for Manufacturing and Packaging under this Agreement. The maximum volume of API that Reliant supplies to Cardinal Health shall not exceed the amount reflected in the Firm Commitment and the next six (6) months of the Rolling Forecast.

  • Field The term “

Time is Money Join Law Insider Premium to draft better contracts faster.